SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing a surge as news circulates about a significant government initiative to buy $200 billion in mortgage bonds, aiming to drive down interest rates. The community is buzzing with expectations of a major rally and potential short squeeze, anticipating increased housing transaction volume due to improved affordability. While some express caution about profit-taking, the overwhelming sentiment points to a renewed bullish outlook for the real estate sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively trending amid intense political discourse following a controversial incident involving federal agents, with the community sharply divided over the justification and legality of the use of force. This event is prompting broader conversations around law enforcement authority and civil liberties, while simultaneously drawing attention to recent policy proposals from the former president regarding housing affordability and mortgage bonds, and reigniting discussions about the Epstein files.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a prominent trending stock, driven by widespread community discussion around its potential prime contractor role in a significant drone-based border security project for Israel, which is being viewed as a major validation of its autonomous defense systems. This news, though unconfirmed by the company, has ignited strong bullish sentiment and speculation about a substantial growth "super cycle" within the broader drone and defense technology sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following highly positive FDA feedback, confirming no additional clinical trials are needed for its lead HS therapy, sonelokimab, paving a clear path to regulatory submission. This significant de-risking event has ignited strong community discussion, fueling speculation of an imminent Merck buyout at a substantially higher valuation and expectations of a potential short squeeze as the market fully re-evaluates the stock's intrinsic value.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is actively discussed amidst political negotiations concerning the extension of Affordable Care Act (ACA) subsidies, with a recent House vote favoring a multi-year extension driving investor attention. The community is sharply divided; optimists foresee a potential short squeeze and significant upside if a bipartisan agreement is reached in the Senate, while others caution about declines if a favorable outcome doesn't materialize. This ongoing debate, coupled with recent analyst attention, places OSCR at the forefront of healthcare sector conversations.

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Inmode Ltd

InMode is a hot topic following a mixed earnings report, where better-than-expected Q3 results and an FDA clearance for Morpheus8 are overshadowed by lowered full-year guidance. Investors are deeply split: many see a heavily undervalued company with a strong balance sheet poised for a rebound, while others point to management's perceived missteps and a challenging aesthetic market as reasons for continued skepticism.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to significant U.S. and U.K. defense contracts, solidifying its position as an end-to-end national security space partner. The community is buzzing with anticipation for the Neutron rocket's debut and strong institutional interest, while some investors debate the current valuation and recent insider share transactions.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

MELANIA CRYPTO is actively trending, stirring heated debate as a political meme coin associated with Melania Trump. While some community members speculate on potential future catalysts, such as an upcoming movie or new deals, to drive a significant price increase, a strong undercurrent of discussion labels it a "scam" or "rug pull," citing substantial reported investor losses and concerns over continuous token dilution. This divergence underscores the highly speculative nature and perceived risks of assets tied to prominent political personalities.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending as investors weigh news of China's scrutiny of a recent AI acquisition against strong demand for its Ray-Ban smart glasses, which has led to a delayed international launch. The community is sharply divided, with many expressing frustration over recent stock performance and questioning the company's substantial AI investments, while others see value in its core advertising business and long-term AI potential ahead of upcoming earnings season.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - What's Next...

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

Key PointsCalifornia-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter...

Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Edgewise Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports...

Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2% - Here's Why

Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2% - Here's What Happened...

Why Edgewise Therapeutics Stock Rocked the Market Today

Key PointsThe biotech gifted quite a holiday present to its investors...

Stock Market Today: 'Santa Rally' Brings New Records for Dow and S&P 500 On Christmas Eve

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here.Happy Wednesday. This is TheStreet's...

<ul class="summary-bullets"><li>Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026.</li><li>The company said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug.</li><li>While Stifel believes the company’s updates still leaves questions on safety, Truist reiterated optimism for the drug’s potential in treating hypertrophic cardiomyopathy.</li></ul>Shares of Edgewise Therapeutics (EWTX) traded 20% higher on Wednesday morning after the company announced positive safety data from the ongoing multi-part mid-stage clinical trial of EDG-7500 in hypertrophic cardiomyopathy (HCM).Earlier this year, the company reported positive results from Part B and Part C 50 mg and 100 mg fixed dose cohorts of the trial in which EDG-7500 administration led to improvements in key HCM disease markers. Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition where the heart muscle thickens, making it harder to pump blood out, stiffening the heart, and potentially causing irregular rhythms, often leading to fatigue, shortness of breath, chest pain, or fainting.<h2 class="st-heading-2">New Study Updates</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-302649113.html">said</a> on Wednesday that it also evaluated a lower 25mg fixed dose in certain participants in Parts B and C and evidence of clinical activity was observed across key HCM disease markers. A favorable safety profile was observed with no clinically meaningful changes in left ventricular ejection fraction (LVEF) and no events of atrial fibrillation (AF), it added. &nbsp;The company also reported interim safety results from Part D of the study and said that EDG-7500 generally had a favorable safety profile and was well tolerated.“The safety profile observed with EDG-7500 to date, across both healthy volunteers and the CIRRUS-HCM trial, supports the potential use of EDG-7500 in diverse HCM patient populations,” the company said.The company, however, said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug. The trial participant was not on active cardiac monitoring at the time and had a history of arrhythmias, including supraventricular tachycardia, the company said.Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026. It is looking forward to starting a late-stage trial by 2026-end.<h2 class="st-heading-2">Experts Are Divided</h2>Stifel thinks the update still leaves questions on safety that'll take more than additional open-label data to disprove. The analyst is now looking forward to longer-term/controlled late-stage data.As per Stifel, the next big catalyst for the stock is data from the late-stage trial being conducted by the company for its drug Sevasemten in patients with Becker muscular dystrophy, a rare, X-linked genetic disorder causing progressive muscle weakness, mainly in males. The results from the trial are expected in the fourth quarter of 2026.Truist, meanwhile, kept a ‘Buy’ rating and $46 price target on Edgewise Therapeutics following the company's updates. Truist remains bullish on the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst told investors in a research note.H.C. Wainwright, which has a $42 price target and ‘Buy’ rating on Edgewise, sees the data reinforcing the drug’s potential for differentiation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EWTX rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/EWTX">EWTX stock</a> is down by 2% this year and by about 12% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-pushes-back-on-trc-capital-mini-tender-bid-at-below-market-price/cLesy0MREv0">Netflix Pushes Back On TRC Capital’s Mini-Tender Bid At Below-Market Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Edgewise Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 

Equity

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 


Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EWTX News

EWTXEdgewise Therapeutics Inc